ES2496592T3 - Proceso para la preparación de Imatinib y compuestos intermedios del mismo - Google Patents

Proceso para la preparación de Imatinib y compuestos intermedios del mismo Download PDF

Info

Publication number
ES2496592T3
ES2496592T3 ES07849757.5T ES07849757T ES2496592T3 ES 2496592 T3 ES2496592 T3 ES 2496592T3 ES 07849757 T ES07849757 T ES 07849757T ES 2496592 T3 ES2496592 T3 ES 2496592T3
Authority
ES
Spain
Prior art keywords
formula
phenyl
methyl
preparation
imatinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07849757.5T
Other languages
English (en)
Inventor
Alessandro Falchi
Ennio Grendele
Riccardo Motterle
Mariano Stivanello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fabbrica Italiana Sintetici SpA (FIS)
Original Assignee
Fabbrica Italiana Sintetici SpA (FIS)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20062208 external-priority patent/ITMI20062208A1/it
Priority claimed from ITMI20070942 external-priority patent/ITMI20070942A1/it
Application filed by Fabbrica Italiana Sintetici SpA (FIS) filed Critical Fabbrica Italiana Sintetici SpA (FIS)
Application granted granted Critical
Publication of ES2496592T3 publication Critical patent/ES2496592T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/58—Amidines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Proceso para la preparación de compuestos de Fórmula 1**Fórmula** en la que R1 representa amino, nitro, halógeno, hidroxi, NH(CO)R3, NHR4, R3 representa 4-(halo-metil)fenilo, 4-(hidroximetil)fenilo, 4-((4-metilpiperazinil)carbonil)fenilo, 4- (alcoxicarbonil)fenilo o 4-[(4-metil-1-piperazinil)metil]fenilo, en donde alcoxi significa alcoxi C1-C4, R4 representa un grupo protector para el grupo amino, que comprende las etapas de: a) hacer reaccionar el -oxo-3-piridinapropanal, una sal del mismo o un enoléter del mismo de Fórmula 17**Fórmula** en la que R2 representa hidrógeno, alquilo C1-C4, bencilo o fenilo, con una arilguanidina de Fórmula 3**Fórmula** en la que R1 tiene el significado descrito anteriormente, para producir el compuesto de Fórmula 19**Fórmula** en la que R1 tiene el significado anterior, y b) ciclar el compuesto intermedio de Fórmula 19 en presencia de una base.

Description

imagen1
DESCRIPCIÓN
Proceso para la preparación de Imatinib y compuestos intermedios del mismo
5 Campo técnico de la invención
El objetivo de la presente invención es un proceso para la preparación de 4-metil-N-3-[4-(3-piridinil)-2-pirimidinil]-1,3bencenodiamina y análogos de la misma, compuestos intermedios útiles para la síntesis de Imatinib, o 4-[(4-metil-1piperazinil)metil]-N-[4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]fenil]benzamida.
10
Estado de la técnica
El mesilato de Imatinib, una molécula de Fórmula 9, es un importante fármaco empleado en el tratamiento de la leucemia mieloide crónica.
15
imagen2
Su preparación se describió en primer lugar en el documento de Patente EP 564409 por Novartis, y se resume en el siguiente Esquema 1. Este documento no informa de los rendimientos de las diversas operaciones preparativas.
imagen3
Sin embargo, el documento de Patente WO 2006/071130 informa que, mediante esta ruta sintética, el rendimiento
2
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES07849757.5T 2006-11-16 2007-11-15 Proceso para la preparación de Imatinib y compuestos intermedios del mismo Active ES2496592T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI20062208 2006-11-16
ITMI20062208 ITMI20062208A1 (it) 2006-11-16 2006-11-16 Processo per la preparazione di imatinib e suoi intermedi
ITMI20070942 ITMI20070942A1 (it) 2007-05-09 2007-05-09 Processo per la preparazione di imatinib e suoi intermedi
ITMI20070942 2007-05-09
PCT/IT2007/000804 WO2008059551A2 (en) 2006-11-16 2007-11-15 Process for the preparation of imatinib and intermediates thereof

Publications (1)

Publication Number Publication Date
ES2496592T3 true ES2496592T3 (es) 2014-09-19

Family

ID=39301633

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07849757.5T Active ES2496592T3 (es) 2006-11-16 2007-11-15 Proceso para la preparación de Imatinib y compuestos intermedios del mismo

Country Status (9)

Country Link
US (2) US8168787B2 (es)
EP (1) EP2074095B1 (es)
JP (1) JP5265562B2 (es)
KR (1) KR101420892B1 (es)
BR (1) BRPI0718812A2 (es)
ES (1) ES2496592T3 (es)
IL (1) IL197954A (es)
RU (1) RU2480461C2 (es)
WO (1) WO2008059551A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2496592T3 (es) * 2006-11-16 2014-09-19 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Proceso para la preparación de Imatinib y compuestos intermedios del mismo
PL215042B1 (pl) * 2008-08-01 2013-10-31 Temapharm Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania imatinibu
EP2582689B1 (en) 2010-06-18 2017-03-01 KRKA, D.D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
ITMI20111309A1 (it) 2011-07-14 2013-01-15 Italiana Sint Spa Procedimento di preparazione di imatinib mesilato
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
CN104284879A (zh) * 2012-05-16 2015-01-14 索尔维公司 1-取代甲叉基化合物的制备
US9388126B2 (en) 2012-07-19 2016-07-12 Drexel University Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
US9630944B2 (en) 2014-04-04 2017-04-25 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Process for preparing Imatinib and salts thereof, free of genotoxic impurity F
CN104003944B (zh) * 2014-05-29 2016-08-24 西北师范大学 一种嘧菌胺的制备方法
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2125310A1 (en) 1971-05-21 1972-11-30 Sterling Drug Inc , New York, NY (V St A) 1-alkyl-1,4-dihydro-4-oxo-1,8-naphtyridine 3-carboxylic acids antibac
US3985757A (en) * 1975-09-17 1976-10-12 E. R. Squibb & Sons, Inc. Pyrazolopyridine ketones
EP0052853A1 (de) 1980-11-24 1982-06-02 Hoechst Aktiengesellschaft Bis-Aminomethyl-anthrachinon-Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2004108699A1 (en) 2003-06-06 2004-12-16 Natco Pharma Limited Process for the preparation of the anti-cancer drug imatinib and its analogues
AU2004246800B2 (en) 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7674901B2 (en) 2004-12-30 2010-03-09 Instytut Farmaceutyczny Process for preparation of imatinib base
ES2496592T3 (es) 2006-11-16 2014-09-19 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Proceso para la preparación de Imatinib y compuestos intermedios del mismo

Also Published As

Publication number Publication date
WO2008059551A3 (en) 2008-12-31
IL197954A0 (en) 2009-12-24
RU2009122692A (ru) 2010-12-27
IL197954A (en) 2013-08-29
JP5265562B2 (ja) 2013-08-14
US20100076189A1 (en) 2010-03-25
EP2074095A2 (en) 2009-07-01
US8334381B2 (en) 2012-12-18
JP2010510203A (ja) 2010-04-02
RU2480461C2 (ru) 2013-04-27
KR20090083455A (ko) 2009-08-03
EP2074095B1 (en) 2014-07-02
BRPI0718812A2 (pt) 2013-12-03
WO2008059551A2 (en) 2008-05-22
US20100234598A1 (en) 2010-09-16
US8168787B2 (en) 2012-05-01
KR101420892B1 (ko) 2014-07-17

Similar Documents

Publication Publication Date Title
ES2496592T3 (es) Proceso para la preparación de Imatinib y compuestos intermedios del mismo
PE20240143A1 (es) Nuevos derivados de quinazolina como inhibidores de sos1 y uso de los mismos
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CO2022001853A2 (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
PE20220133A1 (es) Inhibidores del inflamasoma nlrp3
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
JP2015510886A5 (es)
PE20081636A1 (es) Inhibidores de antranilamida para aurora quinasa
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
AR059249A1 (es) Compuesto amina trisustituido
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
SI1971601T1 (sl) N fenil kinazolin aminski derivati in sorodne spojine kot inhibitorji ERBB tip I receptorske tirozin kinaze za zdravljenje hiperproliferativnih bolezni
AR062209A1 (es) Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos.
BRPI0810929B8 (pt) uso de um composto de fórmula 1
AR067886A1 (es) Derivados de acido azabifenilaminobenzoico
AR057997A1 (es) Compuestos de heteroarilo biciclicos que contienen nitrogeno y metodos de uso
AR062965A1 (es) Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos
EA200700141A1 (ru) Новые аминоциклические производные мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназы
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
NZ587518A (en) Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
PE20080835A1 (es) Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a
EA201000101A1 (ru) Производные пиримидина 934